指南与共识认知障碍与痴呆

阿尔茨海默病的临床诊断:国际工作组建议

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
指南 / 共识 · Lancet Neurol · 2021-04-29

国际工作组针对2018年NIA-AA纯生物学定义在临床实践中的局限提出建议。工作组指出生物标志物阳性可见于认知未受损者及其他脑病共病,建议阿尔茨海默病诊断应限于生物标志物阳性且具有特定临床表型者,仅生物标志物阳性而认知未受损者应视为进展风险人群。

要点

  • 阿尔茨海默病诊断需生物标志物阳性加特定临床表型,不能仅凭生物标志物。
  • 生物标志物阳性但认知未受损者仅视为进展为阿尔茨海默病的风险人群。
  • 生物标志物阳性可见于其他脑病共病,解读时需结合临床表型。

核心结论

  • 阿尔茨海默病诊断应限于生物标志物阳性且具有特定阿尔茨海默病表型的人群。
  • 仅生物标志物阳性而认知未受损的个体应只视为进展为阿尔茨海默病的风险人群。

研究设计与样本

  • 国际工作组基于证据提出的个人观点(Personal View),提出生物标志物在临床诊断中的使用建议。

主要发现

  • 认知未受损个体可有淀粉样蛋白β和tau病理的生物标志物证据,但常一生不出现临床表现。
  • 在其他存在阿尔茨海默病病理作为共病的脑病中,也可观察到阳性的阿尔茨海默病生物标志物模式。

关键数值与推荐

  • 阿尔茨海默病诊断应限于生物标志物阳性且具有特定阿尔茨海默病表型者。
  • 生物标志物阳性而认知未受损者应仅视为进展为阿尔茨海默病的风险人群。

临床怎么用

  • 临床诊断阿尔茨海默病时不应仅依据生物标志物阳性,需结合特定临床表型。
  • 对生物标志物阳性但认知未受损者,应告知其为进展风险人群而非阿尔茨海默病患者。

局限性

  • 本文为个人观点(Personal View),非系统评价或指南制定方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid β and tau pathology but will often not develop clinical manifestations in their lifetime. Furthermore, a positive Alzheimer's disease pattern of biomarkers can be observed in other brain diseases in which Alzheimer's disease pathology is present as a comorbidity. In this Personal View, the International Working Group presents what we consider to be the current limitations of biomarkers in the diagnosis of Alzheimer's disease and, on the basis of this evidence, we propose recommendations for how biomarkers should and should not be used for diagnosing Alzheimer's disease in a clinical setting. We recommend that Alzheimer's disease diagnosis be restricted to people who have positive biomarkers together with specific Alzheimer's disease phenotypes, whereas biomarker-positive cognitively unimpaired individuals should be considered only at-risk for progression to Alzheimer's disease.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 2021. PMID: 33933186. doi:10.1016/S1474-4422(21)00066-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。